Researchers from the National Institutes of Health and the Huntsman Cancer Institute have developed a novel novel drug that targets cancer-fighting molecules in the brain that are particularly active during cancer therapy.
The breakthrough was announced Monday in the journal Nature.
The researchers are led by Thomas P. Schaffner, a professor of biomedical engineering and of bioengineering at the University of Texas Health Science Center at Houston.
“Our work shows that our nanoparticles can be used to deliver targeted molecules that are highly specific to cancer cells,” said Dr. Schiffner.
“We have developed new nanoparticles that are very small and fast-acting, with high-bandwidth communications.”
The nanoparticles were synthesized from two different types of molecules that interact with DNA.
They are one type of protein that is produced by the body and two types of proteins that are produced by cancer cells.
“This work has the potential to change the way cancer cells are treated, which is critical to controlling and preventing the spread of cancer,” said John A. Schafer, a research professor at the Johns Hopkins University Applied Physics Laboratory and the study’s first author.
The new nanoparticle has been shown to inhibit cancer cells in mouse models.
They were able to block the DNA binding to the tumor cells, but not to their outer membrane, which protects them from the immune system.
“The researchers believe the nanoparticles could be used in the treatment of many types of cancer, such as brain cancer, glioblastoma, lymphoma, breast cancer, ovarian cancer and prostate cancer,” Schaffers said.
“It is important that the cancer cells themselves are treated with the nanoparticle and not the nanoparticulates.”
The researchers also demonstrated that the nanoparts are able to target the molecules involved in the signaling pathway to the cancer.
“In this way, we have demonstrated the ability to target specific DNA molecules,” said David M. Hsu, a co-author of the study and a researcher at the National Cancer Institute.
“Because the nanopots are very active in the tumor, the treatment is very targeted.”
Researchers have been trying to develop drugs to target cancer-causing proteins for years.
The research team is the first to show that they are able, in combination with other molecules, to prevent cancer cells from making these proteins.
The discovery will be important for the treatment and research of cancer.
It will also help researchers understand how cancer cells communicate, the way they interact with the immune and how they communicate with other cells.
It is possible that nanoparticles, when combined with other drugs, could be an important step toward developing drugs that can stop or slow the growth of cancer cells or help treat the immune response to them.
The team also said that the drugs will be useful for the prevention of brain cancer.
This could have potential applications in cancer therapy for a number of different conditions, including stroke, Alzheimer’s, Parkinson’s and other forms of dementia.
The nanopartices are being developed as part of the NIH’s National Nanotechnology Initiative.
The NIH program is a $7 billion effort to develop, commercialize and commercialize novel nanotechnology-based therapies for the human body and the environment.
“With this work, we are making an important contribution to understanding how brain cancer cells interact with other cell types, the communication pathways they use, and how we can prevent or slow tumor growth,” Schafer said.
Dr. John Hsu was a coauthor of a study in Nature.
For more on this story, visit the Huntsmans Cancer Institute website.